We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biomarker Panel Validated for Parkinson's Disease Diagnosis

By LabMedica International staff writers
Posted on 08 Sep 2009
A protein biomarker panel identified Parkinson's disease (PD) patients using blood serum samples.

Quantitative two-dimensional (2D) gel electrophoresis was used to identify protein biomarkers in serum for diagnosing PD from routinely collected blood samples. More...
Fifty-seven protein biomarkers, which had been discovered using retrospective blood serum samples from various neurodegenerative diseases, were then applied specifically to PD samples in a prospective clinical investigation using freshly collected blood serum from PD patients and age-matched normal controls.

When applied to the PD samples, a 21-protein set had sensitivity of 93.3% (52 of 56 PD correctly classified) and specificity of 92.9% (28 of 30 controls correctly classified); 15 of 15 patients with mild and 28 of 30 with moderate to severe symptoms were correctly classified, as were all 6 PD samples from an independent site.

The analytic technology that forms the basis for the NuroProPD test for PD being is being commercialized by Transgenomic (Huston, TX, USA) according to a licensing/collaboration agreement with Power3 Medical (Omaha, NE, USA), signed in early 2009. The study represents a significant validation milestone in the clinical development of the NuroProPD diagnostic assay.

Craig Tuttle, CEO of Transgenomic, said, "We are completing the clinical validation of the assay in our [clinical laboratory approved amendments] CLIA-certified molecular testing laboratory and will be launching the assay in the very near future."

Power3 also operates a CLIA certified laboratory and employs sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for Parkinson's and Alzheimer's diseases, amyotrophic lateral sclerosis, as well as breast cancer.

Related Links:
Transgenomic
Power3 Medical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.